Abstract:
:Follicular lymphoma (FL), the most common subtype of indolent lymphoma, is usually diagnosed at an advanced stage (III-IV), although patients are often asymptomatic. Traditionally, a palliative approach to management has been taken, cycling through watchful waiting, radiotherapy, oral alkylating agents and, eventually, combination chemotherapy, as deemed necessary. However, accumulating evidence suggests that in patients requiring treatment, early initiation of an anthracycline-based regimen may achieve better response rates and progression-free survival compared with reserving such options until late in the course of disease. Delivery of myelosuppressive chemotherapy has been facilitated by the availability of granulocyte colony-stimulating factors. Incorporation of the anti-CD20 monoclonal antibody rituximab into upfront chemotherapy regimens further improves outcomes. With a trend towards early use of rituximab chemotherapy combinations, median survival appears to have increased in patients with FL. A number of issues remain to be addressed by ongoing research. These include identification of the most effective rituximab chemotherapy regimen, the impact of treatment on responsiveness to future treatment, the need for rituximab maintenance therapy and the place of newer treatments. Clearly, there are arguments in favour of considering early aggressive rituximab and chemotherapy regimens in patients with FL requiring treatment, and it is hoped that new prognostic tools will help us to more accurately identify which patients are most likely to benefit.
journal_name
Drugsjournal_title
Drugsauthors
Pettengell Rdoi
10.2165/11317050-000000000-00000subject
Has Abstractpub_date
2009-01-01 00:00:00pages
1727-37issue
13eissn
0012-6667issn
1179-1950pii
1journal_volume
69pub_type
杂志文章相关文献
DRUGS文献大全abstract::Despite remarkable advances in cardiovascular therapeutics, sudden cardiac death remains a significant problem. In this review, data from clinical trials and other studies on antiarrhythmic therapies have been evaluated in order to determine effective strategies for the prevention of sudden cardiac death in high risk ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199754020-00003
更新日期:1997-08-01 00:00:00
abstract::The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0565-4
更新日期:2016-04-01 00:00:00
abstract::During the 40 years since the initial synthesis of fluorouracil, there have been many attempts to improve fluoropyrimidine chemotherapy. These have included the utilisation of different schedules of fluorouracil administration, modulation of the metabolism of fluorouracil with other drugs to increase its therapeutic b...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958003-00016
更新日期:1999-01-01 00:00:00
abstract::Suvorexant (Belsomra(®)), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. Variations in the levels of the neuropeptides orexin A and orexin B have been linked to circadian rhythms and wakefulness. Orexin-producing neuro...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0294-5
更新日期:2014-10-01 00:00:00
abstract::The oral deoxyguanosine nucleoside analogue entecavir (Baraclude®) has potent activity against hepatitis B virus (HBV) and a high genetic barrier to resistance. This article reviews the clinical efficacy and tolerability of entecavir in the treatment of chronic hepatitis B in patients with decompensated liver disease,...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11208510-000000000-00000
更新日期:2011-12-24 00:00:00
abstract::Heparin remains the most effective antithrombotic drug. It acts by combining with plasma antithrombin, thereby accelerating the neurtalisation of thrombin and other acitvated coagulation factors. Full-dose intravenous heparin is indicated in all cases of pulmonary embolism and established deep venous thrombosis, unles...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197713010-00005
更新日期:1977-01-01 00:00:00
abstract::Sore throats are most commonly due to infections, many of which are viral and do not require specific treatment. Symptoms and signs of the common cold, influenza or croup, the occurrence of conjunctivitis in some adenoviral infections, generalised lymphadenopathy and splenomegaly in glandular fever or the presence of ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199040060-00007
更新日期:1990-12-01 00:00:00
abstract::Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more fre...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200969060-00004
更新日期:2009-01-01 00:00:00
abstract::Dopamine agonists (DAs) represent an excellent treatment option for patients with Parkinson's disease, in both the early and advanced stages of the disease, improving motor symptoms, lowering the incidence of motor complications, and addressing several non-motor symptoms. Indeed, each of these compounds have different...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01103-2
更新日期:2019-05-01 00:00:00
abstract::Currently available quinolones are either inactive or marginally active against anaerobic bacteria. This review summarises the in vitro activity of currently available as well as experimental quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxa...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199500492-00012
更新日期:1995-01-01 00:00:00
abstract::Anagrelide (Agrylin, Xagrid) is an oral imidazoquinazoline agent which is indicated in Europe for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of or refractory to their current therapy, and in the US for the reduction of elevated platelet counts and t...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666010-00006
更新日期:2006-01-01 00:00:00
abstract::Flecainide is a Class I antiarrhythmic drug of the local anaesthetic type. It can be given either intravenously or orally and its pharmacokinetic properties allow relatively long (12 hours) dosing intervals with oral administration. In several open and a few controlled therapeutic trials, orally administered flecainid...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198529010-00001
更新日期:1985-01-01 00:00:00
abstract::Cardiovascular disease continues to be the principal cause of death in Western countries. Epidemiological studies have repeatedly demonstrated a striking relationship between blood pressure and the risk of cardiovascular disease in that those with the highest levels of blood pressure are at the greatest risk for subse...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198600314-00003
更新日期:1986-01-01 00:00:00
abstract::Janus kinase (JAK) is a signal transducer and activator of a protein transcription system that transduces signals from cell surface cytokine and growth factor receptors to the nucleus. Recently developed JAK inhibitors (JAKinibs) inhibit JAKs non-selectively or selectively and down-regulate the effects of correspondin...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01349-1
更新日期:2020-08-01 00:00:00
abstract::Metabolites of arachidonic acid have a broad range of physiological functions in the gastrointestinal tract, and seem to be involved in certain disturbances of gastrointestinal integrity and function. Prostaglandins inhibit gastric acid secretion, apparently via an adenylate cyclase-linked receptor, and also stimulate...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198700331-00007
更新日期:1987-01-01 00:00:00
abstract::Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight los...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/11640860-000000000-00000
更新日期:2012-10-22 00:00:00
abstract::Early identification of infants with sickle cell disease (SCD) by newborn screening, now universal in all 50 states in the US, has improved survival, mainly by preventing overwhelming sepsis with the early use of prophylactic penicillin. Routine transcranial Doppler screening with the institution of chronic transfusio...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11632890-000000000-00000
更新日期:2012-05-07 00:00:00
abstract::Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01067-3
更新日期:2019-02-01 00:00:00
abstract::For patients with superficial bladder tumours intravesical treatment or prophylaxis with thiotepa, doxorubicin, mitomycin C or Bacillus Calmette-Guerin has added a useful dimension to management, although the precise indications for each regimen remain to be better defined. For patients with metastatic bladder cancer ...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-198938020-00009
更新日期:1989-08-01 00:00:00
abstract::For almost half a century, the first-line treatment for ovulation induction in cases of anovulation, unexplained infertility, or mild male factor has been clomifene (clomiphene citrate). Clomifene is an effective and safely used oral agent, but is known to have relatively common antiestrogenic endometrial and cervical...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666170-00001
更新日期:2006-01-01 00:00:00
abstract::MenB-FHbp (bivalent rLP2086; Trumenba®) is a recombinant protein-based vaccine targeting Neisseria meningitidis serogroup B (MenB), which has recently been licensed in the EU for active immunization to prevent invasive disease caused by MenB in individuals ≥ 10 years of age. The vaccine, which contains a variant from ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0869-7
更新日期:2018-02-01 00:00:00
abstract::Hepatitis E accounts for the major part of enterally transmitted non-A, non-B hepatitis worldwide. Its agent, the hepatitis E virus (HEV), is a small, single-stranded RNA virus. Only one serotype of HEV is recognised. Infection results in protective immunity with long-lived neutralising antibodies. In developing count...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200464140-00002
更新日期:2004-01-01 00:00:00
abstract::The bacteria most commonly responsible for early-onset (materno-fetal) infections in neonates are group B streptococci, enterococci, Enterobacteriaceae and Listeria monocytogenes. Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, are the main pathogens in late-onset (nosocomial) infections, es...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958030-00003
更新日期:1999-09-01 00:00:00
abstract::Administration of unopposed postmenopausal estrogen therapy protects against coronary heart disease (CHD) in women. This is mediated, in part, through beneficial effects on lipid and lipoprotein metabolism. Fewer data are available with regard to CHD risk reduction when a progesterone is required in addition to estrog...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199400472-00005
更新日期:1994-01-01 00:00:00
abstract::The clonidine transdermal therapeutic system (TTS) is a cutaneous delivery device which provides therapeutically effective doses of clonidine at a constant rate over 7 days. In clinical trials it reduces blood pressure in patients with mild to moderate hypertension as effectively as oral clonidine but with greater sta...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198835020-00003
更新日期:1988-02-01 00:00:00
abstract::Because platelets are so important in thrombus formation, drugs which inhibit platelet function (the 'antiplatelet drugs') have considerable potential as antithrombotic agents. Among the antiplatelet drugs, only aspirin, sulphinpyrazone, dipyridamole, hydroxychloroquine, and clofibrate have had wide clinical trial. Th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197918060-00002
更新日期:1979-12-01 00:00:00
abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01417-6
更新日期:2020-11-01 00:00:00
abstract::The antihypertensive effects of the regular immediate release formulation of verapamil (verapamil IR) and the newer sustained release formulation of verapamil (verapamil SR) were compared in Hispanic patients with untreated essential hypertension. Verapamil IR was given in 3 divided doses (80 or 160mg 3 times daily) a...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-199200441-00002
更新日期:1992-01-01 00:00:00
abstract::Pain represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to more than 60%, depending on the population. The impact of pain on economies is enormous, with the cost of back pain alone equivalent to more than one-fifth of one country's total health expenditure and 1....
journal_title:Drugs
pub_type: 杂志文章,评审
doi:
更新日期:2003-01-01 00:00:00
abstract::Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01463-0
更新日期:2021-01-06 00:00:00